{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:16:19Z","timestamp":1784556979799,"version":"3.55.0"},"reference-count":0,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Graves\u2019 disease is a common cause of hyperthyroidism. Three therapies have been used for decades: pharmacologic therapy, surgery and radioiodine. In case of adverse events, especially agranulocytosis or hepatotoxicity, pre-treatment with Lugol\u2019s solution containing iodine\/potassium iodide to induce euthyroidism before surgery could be advocated, but this has rarely been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients hospitalised due to uncontrolled hyperthyroidism at the Karolinska University Hospital 2005\u20132015 and treated with Lugol\u2019s solution were included. All electronic files were carefully reviewed manually, with focus on the cause of treatment and admission, demographic data, and effects of iodine on thyroid hormone levels and pulse frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-seven patients were included. Lugol\u2019s solution had been chosen due to agranulocytosis in 9 (33%), hepatotoxicity in 2 (7%), other side effects in 11 (41%) and poor adherence to medication in 5 (19%). Levels of free T4, free T3 and heart rate decreased significantly after 5\u20139 days of iodine therapy (free T4 53\u201320\u2009pmol\/L,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0002; free T3 20\u20136.5\u2009pmol\/L,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04; heart rate 87\u201376 beats\/min\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0007), whereas TSH remained unchanged. Side effects were noted in 4 (15%) (rash\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092, rash and vomiting\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091, swelling of fingers\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). Thyroidectomy was performed in 26 patients (96%) and one was treated with radioiodine; all treatments were without serious complications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment of uncontrolled hyperthyroidism with Lugol\u2019s solution before definitive treatment is safe and it decreases thyroid hormone levels and heart rate. Side effects were limited. Lugol\u2019s solution could be recommended pre-operatively in Graves\u2019 disease with failed medical treatment, especially if side effects to anti-thyroid drugs have occurred.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-17-0025","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T20:27:54Z","timestamp":1490128074000},"page":"200-205","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":13,"title":["Rescue pre-operative treatment with Lugol\u2019s solution in uncontrolled Graves\u2019 disease"],"prefix":"10.1530","volume":"6","author":[{"given":"Jan","family":"Calissendorff","sequence":"first","affiliation":[{"name":"1Department of EndocrinologyMetabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden"},{"name":"2Department of Molecular Medicine and SurgeryKarolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Falhammar","sequence":"additional","affiliation":[{"name":"1Department of EndocrinologyMetabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden"},{"name":"2Department of Molecular Medicine and SurgeryKarolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/6\/4\/200.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/6\/4\/200.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:42:11Z","timestamp":1784554931000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/6\/4\/200-205\/35239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":0,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/ec-17-0025","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}